Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 7/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 7/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15587409 | 0.86 | MAP4K4 (0.47) | MAP4K4CARM1PRMT6OPRL1 | |
| SCHEMBL19016213 | 0.85 | ALDH1A1 (0.41) | MAP4K4CARM1PRMT6OPRL1KCNH2 | |
| SCHEMBL19008146 | 0.82 | MAP4K4 (0.44) | MAP4K4CARM1PRMT6ALDH1A1 | |
| SCHEMBL19008167 | 0.82 | ALDH1A1 (0.45) | MAP4K4CARM1PRMT6KCNH2KDM4E | |
| SCHEMBL18626597 | 0.82 | ALDH1A1 (0.49) | MAP4K4KCNH2KDM4EALDH1A1POLB | |
| SCHEMBL15587406 | 0.81 | MAP4K4 (0.48) | MAP4K4CARM1PRMT6OPRL1KDM4E | |
| SCHEMBL18626535 | 0.80 | TSHR (0.43) | MAP4K4CARM1PRMT6OPRL1KCNH2 | |
| SCHEMBL19008163 | 0.79 | LMNA (0.37) | MAP4K4CARM1PRMT6KCNH2KDM4E | |
| SCHEMBL18626596 | 0.79 | MAP4K4 (0.45) | MAP4K4CARM1PRMT6OPRL1ALDH1A1 | |
| SCHEMBL19008166 | 0.78 | BACE1 (0.47) | MAP4K4CARM1PRMT6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | MAP4K4 662/4885CARM1 2613/4885PRMT6 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.